Loading
Extracellular Vesicles in Disease · Journal article
International Journal of Current Science Research and Review · August 10, 2026
A consensus or society position rather than new primary data.
This is a narrative systematic review summarizing exosome biology, isolation technologies, and emerging roles in cancer detection and therapy from 2015–2025 literature. The review identifies exosomes as intercellular messengers involved in metastasis and highlights microfluidics and CRISPR-Cas pairing as innovative approaches, but does not report meta-analytic synthesis, clinical trial outcomes, or quantified effect sizes.
Systematic review. Published scientific literature on exosomes, isolation methods, and cancer biology from 2015–2025.. Intervention: Exosome isolation methods (including microfluidics and spectroscopy) and exosome-based cancer detection and therapeutic approaches.. Compared with: Synthetic nanoparticles (noted as less advantageous than exosomes with respect to biocompatibility and blood-brain barrier penetration).. International databases; geography of primary studies not specified..
Exosomes are nano-sized (30–150 nm) extracellular vehicles released by cells through the endosomal route. Exosomes function as intercellular message carriers deeply involved in cancer metastasis. Innovative isolation methods such as microfluidics have significantly reduced isolation time.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should view exosomes as an emerging platform with potential for targeted cancer therapy and drug delivery; however, the review does not provide quantified clinical outcome data or evidence of superiority over existing treatments, so clinical adoption decisions should await controlled trials and standardization.
A systematic review synthesizing current knowledge on exosome biology, isolation methods, and cancer applications; provides an appraisal of the field rather than original clinical trial data or a practice recommendation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should view exosomes as an emerging platform with potential for targeted cancer therapy and drug delivery; however, the review does not provide quantified clinical outcome data or evidence of superiority over existing treatments, so clinical adoption decisions should await controlled trials and standardization.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract: Exosomes are a subset of nano-sized (30–150 nm) extracellular vehicles (EVs) released by cells through the endosomal route, you know like they get made inside and then pushed out. Objective: The primary objective of this scientific review is to give a broad and current appraisal of the intricate biological layout of exosomes, plus modern isolation technologies (for instance microfluidics and spectroscopy), and finally their clinical meaning for cancer detection and treatment. Methods: This article is arranged following systematic review logic based on credible scientific sources from the last decade 2015–2025. Data collection involved international databases, including PubMed, Scopus and Web of Science. The analysis looks at how exosome biogenesis connects with drug delivery systems (DDS), and how that whole interplay affects the tumor microenvironment, using both qualitative and quantitative comparative approaches. The guidelines from the International Society for Extracellular Vesicles (ISEV) were used as a kind of standard for study rigor. Key Findings: A growing body of research suggests that exosomes work as important intercellular message carriers, meaning they are deeply involved in cancer metastasis. Their nano-sized form, the potential to move across the blood-brain barrier (BBB), and their inherent biocompatibility make them a stronger, more natural alternative in comparison with synthetic nanoparticles. Innovative methods such as microfluidics have cut the isolation time a lot, and pairing exosomes with the CRISPR-Cas system has basically opened new directions for gene therapy. In the end, the review also tackles difficulties in standardization and large-scale production, while stressing that exosome engineering is likely the upcoming step change for precision cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.